

Itvisma® (onasemnogene abeparvovec-brve) Prior Authorization Form

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____

Drug Information

Physician billing (HCPCS code: _____ **)** **Pharmacy billing (NDC:** _____ **)**

Projected Date of Infusion: _____ **Dose:** _____ **Regimen:** _____

Billing Provider Information

Provider NPI: _____ **Provider Name:** _____

Provider Phone: _____ **Provider Fax:** _____

Name of outpatient hospital facility where Itvisma® will be delivered to and administered at:

Prescriber Information

Prescriber NPI: _____ **Prescriber Name:** _____

Prescriber Phone: _____ **Prescriber Fax:** _____ **Specialty:** _____

Criteria

***Page 1 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.**

For Authorization: (only 1 infusion will be approved per member per lifetime)

1. What is the member's diagnosis?

Spinal Muscular Atrophy (SMA)

A. Has the diagnosis been confirmed by molecular genetic testing? Yes ___ No ___

i. If yes, please submit results of genetic testing.

B. Does member have biallelic mutations in the survival motor neuron gene 1 (SMN1)? Yes ___ No ___

Other: _____

3. Is member able to sit? Yes ___ No ___

4. Is member able to walk without assistance (i.e., able to walk without assistive devices)? Yes ___ No ___

5. Is Itvisma® prescribed by a neurologist or specialist with expertise in the treatment of SMA (or an advanced care practitioner with a supervising physician who is a neurologist or specialist with expertise in the treatment of SMA)? Yes ___ No ___

6. Please provide member's baseline anti-AAV9 antibody titers: _____

7. Does prescriber agree to monitor liver function tests and platelet counts at baseline and as directed by the package labeling? Yes ___ No ___

8. Does prescriber agree to administer systemic corticosteroids starting 1 day prior to the Itvisma® infusion and continue as recommended in the prescribing information based on member's liver function? Yes ___ No ___

9. Will the facility where Itvisma® will be delivered to and administered at, and pharmacy if applicable, adhere to the storage and handling requirements in the Itvisma® prescribing information? Yes ___ No ___

(Page 1 of 2)

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit
Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Itvisma[®] (onasemnogene abeparvovec-brve) Prior Authorization Form**Member Name:** _____ **Date of Birth:** _____ **Member ID#:** _____**Criteria*****Page 2 of 2—Please complete and return all pages. Failure to complete all pages will result in processing delays.****For Authorization: (continued)**

10. Is member currently receiving treatment with Spinraza[®]? Yes ___ No ___
11. Is member currently receiving treatment with Evrysdi[®]? Yes ___ No ___
12. Has member previously received Zolgensma[®]? Yes ___ No ___
13. Will Spinraza[®] or Evrysdi[®] treatment be used concomitantly with Itvisma[®]? Yes ___ No ___

Additional Information: _____

(Page 2 of 2)

Prescriber Signature: _____ **Date:** _____

(By signature, the physician confirms the criteria information above is accurate and verifiable in patient records.) **Specific information/ documentation will be requested if necessary. Failure to complete this form in full will result in processing delays.**

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit
Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.